Rotigotine: A Dopamine D2/D3 Receptor Agonist for Parkinson’s Disease Research

Executive Summary: Rotigotine is a highly selective dopamine D2 and D3 receptor agonist with Ki values of 13 nM and 0.71 nM, respectively (APExBIO). It demonstrates significant antiparkinsonian activity in preclinical models (Bertaina-Anglade et al., 2006). Rotigotine also binds 5-HT1A and adrenergic α2B receptors, providing a broader neuropharmacological profile. Its efficacy in animal models supports its use in cell-based and in vivo assays for dopamine receptor function. The compound is supplied by APExBIO at ≥98% purity and is intended strictly for research use.

Biological Rationale

Parkinson’s disease is characterized by degeneration of dopaminergic neurons in the substantia nigra, leading to motor deficits and, frequently, neuropsychiatric symptoms including depression (Bertaina-Anglade et al., 2006). Dopamine D2 and D3 receptors play critical roles in mediating the effects of dopamine in the central nervous system. Agonists targeting these receptors can ameliorate both motor and some non-motor symptoms by restoring dopaminergic signaling. Rotigotine is utilized to probe these mechanisms due to its strong selectivity and potency at D2 and D3 receptors. Additionally, comorbidity with depression in Parkinson's disease is reported at rates of 25–40%, emphasizing the need for compounds that can address multiple symptom domains (Bertaina-Anglade et al., 2006).

Mechanism of Action of Rotigotine

Rotigotine acts as a non-ergolinic dopamine receptor agonist. It exhibits high binding affinity at dopamine D2 (Ki = 13 nM) and D3 (Ki = 0.71 nM) receptors, and moderate affinity for 5-HT1A and adrenergic α2B receptors (APExBIO). By stimulating post-synaptic D2/D3 receptors, rotigotine compensates for dopamine deficits in Parkinsonian models, improving locomotor activity and motor coordination (Bertaina-Anglade et al., 2006). Additional serotonergic and adrenergic receptor interactions may underlie observed effects on mood and behavioral endpoints.

Evidence & Benchmarks

• Rotigotine at 5 mg/kg increased spontaneous motor activity in rats after 3–5 days of administration (Bertaina-Anglade et al., 2006).
• In forced swim tests, 5 mg/kg rotigotine enhanced rat mobility, indicating antidepressant-like effects (Bertaina-Anglade et al., 2006).
• Rotigotine (0.5, 1, 5 mg/kg/day) reversed active avoidance deficits in learned helplessness models after 3–5 days (Bertaina-Anglade et al., 2006).
• U-shaped dose–response observed in open-field tests with 0.3 mg/kg every 2 days, indicating optimal dosing is critical (Bertaina-Anglade et al., 2006).
• Rotigotine’s molecular formula is C19H25NOS; its molecular weight is 315.47 g/mol (APExBIO).
• Solubility: ≥58 mg/mL in DMSO, ≥25.25 mg/mL in ethanol, insoluble in water (APExBIO).
• Purity: ≥98.00%; storage recommended at -20°C (APExBIO).

For additional receptor profile and pharmacological context, see Rotigotine: A Dopamine Receptor Agonist for Parkinson’s D.... This article extends the referenced piece by providing updated evidence on behavioral endpoints and detailed workflow integration parameters.

Applications, Limits & Misconceptions

Rotigotine is primarily used in preclinical research on Parkinson’s disease and related disorders. It is also valuable in cell-based assays to investigate dopaminergic receptor function and signaling pathways. Its high affinity for D2/D3 receptors enables precise modulation in neuroscience research (APExBIO). However, it is strictly for research purposes and not for diagnostic or therapeutic use in humans.

Common Pitfalls or Misconceptions

• Rotigotine is not suitable for use in aqueous (water-based) systems due to insolubility (APExBIO).
• Long-term storage of solutions is discouraged; instability may compromise activity (APExBIO).
• The compound is not approved for clinical or diagnostic purposes—research use only (APExBIO).
• High doses may increase locomotor activity non-specifically, potentially masking specific behavioral endpoints (Bertaina-Anglade et al., 2006).
• Patch formulations are not applicable in rodent models due to poor skin permeation and fur interference (Bertaina-Anglade et al., 2006).

Workflow Integration & Parameters

For in vitro assays, rotigotine can be dissolved in DMSO at concentrations ≥58 mg/mL or in ethanol at ≥25.25 mg/mL. It should be aliquoted and stored at -20°C to preserve stability; use solutions promptly to minimize degradation (APExBIO). In vivo studies typically use dosing ranges from 0.05 mg/kg to 5 mg/kg, with behavioral endpoints reached within 3–5 days of repeated dosing (Bertaina-Anglade et al., 2006). For a comprehensive overview of integrating dopamine agonists into neuroscience workflows, see Rotigotine: A Dopamine Receptor Agonist for Parkinson’s D.... This article details updated dosing benchmarks and solubility data for optimized assay designs.

Conclusion & Outlook

Rotigotine is a validated dopaminergic tool compound with well-defined molecular and pharmacological parameters. Its selective D2/D3 receptor agonism and robust preclinical efficacy support its continued use in Parkinson’s disease and neuropsychiatric research. APExBIO supplies rotigotine at high purity, with rigorous quality controls for reproducibility. Ongoing research will further clarify its full pharmacodynamic profile and potential roles in neurobiology. For detailed product information and ordering, refer to the Rotigotine A3776 product page.